Olaparib: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel

Revision as of 09:36, 23 October 2023 view source Alexander Berchansky (talk \| contribs) 29,637 edits No edit summary ← Older edit		Latest revision as of 12:30, 18 January 2024 view source Michal Harel (talk \| contribs) 31,761 edits No edit summary
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='~~Caption for this structure~~' scene='10/1001156/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Olaparib' scene='10/1001156/Cv/1'>
	Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults (see [[BRCA]]). It is a PARP inhibitor, inhibiting [[Poly (ADP-ribose) polymerase\|poly ADP ribose polymerase]] (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.<ref name="a7">PMID:19553641</ref> See also [https://en.wikipedia.org/wiki/Olaparib Olaparib].		Olaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults (see [[BRCA]]). It is a PARP inhibitor, inhibiting [[Poly (ADP-ribose) polymerase\|poly ADP ribose polymerase]] (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers.<ref name="a7">PMID:19553641</ref> See also [https://en.wikipedia.org/wiki/Olaparib Olaparib].